|
Re: RESVERLOGIX ANNOUNCES VOTING RESULTS FROM THE 2022 MEETING OF SHAREHOLDERS
|
7
|
Resverlogix Corp.
|
Jun 22, 2022 10:30AM
|
|
Re: RESVERLOGIX ANNOUNCES VOTING RESULTS FROM THE 2022 MEETING OF SHAREHOLDERS
|
4
|
Resverlogix Corp.
|
Jun 27, 2022 07:35PM
|
|
Re: Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
|
6
|
Resverlogix Corp.
|
Sep 06, 2017 04:59PM
|
|
Re: Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
|
2
|
Resverlogix Corp.
|
Sep 05, 2017 10:35AM
|
|
Re: Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
|
2
|
Resverlogix Corp.
|
Sep 07, 2017 09:19AM
|
|
Re: Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
|
3
|
Resverlogix Corp.
|
Sep 05, 2017 01:50PM
|
|
Re: Resverlogix Closes Extension of Maturity Date of Loan and Announces Private Placement
|
1
|
Resverlogix Corp.
|
Sep 05, 2017 02:47PM
|
|
Re: Resverlogix Corp. Selected to Present at Cavendish Global Health Impact Forum
|
5
|
Resverlogix Corp.
|
Oct 23, 2015 03:37PM
|
|
Re: Resverlogix Expands Phase 2b Clinical Trial for COVID-19
|
10
|
Resverlogix Corp.
|
Feb 17, 2022 12:31PM
|
|
Re: Resverlogix Files 2017 Year-End Disclosure Documents and Announces Plans to Host a Symposium at the European Society of Cardiology Congress 2017
|
5
|
Resverlogix Corp.
|
Jul 26, 2017 06:28PM
|
|
Re: Resverlogix In Active Discussions With The Kingdom of Morocco’s Ministry of Health For The Launch Of COVID-19 Clinical Studies With First-In-Class Dru
|
9
|
Resverlogix Corp.
|
Nov 02, 2021 12:19PM
|
|
Re: Resverlogix is looking at issuing some none tradable financial instruments
|
3
|
Resverlogix Corp.
|
Sep 06, 2015 10:20AM
|
|
Re: Resverlogix NYAS Symposium notes
|
1
|
Resverlogix Corp.
|
Apr 30, 2016 09:36AM
|
|
Re: Resverlogix NYAS Symposium notes
|
2
|
Resverlogix Corp.
|
Apr 29, 2016 03:06PM
|
|
Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
|
4
|
Resverlogix Corp.
|
Oct 04, 2023 01:25PM
|
|
Re: Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
|
3
|
Resverlogix Corp.
|
Jul 10, 2017 03:20PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
2
|
Resverlogix Corp.
|
Jun 22, 2020 05:45PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
4
|
Resverlogix Corp.
|
Jun 22, 2020 05:54PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
2
|
Resverlogix Corp.
|
Jun 22, 2020 06:10PM
|
|
Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
|
2
|
Resverlogix Corp.
|
Jun 22, 2020 06:27PM
|
